Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Injectable Aesthetics
    • Dermatological Skincare
    • Therapeutic Dermatology
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2024
    • The aesthetic impact of medication-driven weight loss
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Podcasts
  • Innovation
    • Skin Science by Galderma
    • Bringing innovation to life
    • Partnering
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • For society
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Home
  • Investors

Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress

Press release

Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative

Press release

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

Press release

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

Press release

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Press release

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Press release

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

Press release

Galderma launches CETAPHIL® line for sensitive skin and a new DAYLONG® sun protection product in Switzerland

Press release

New study reveals the impact of ‘hidden acne’ on quality of life

Press release

Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases

Press release

Pagination

  • Previous page Previous Page
  • Next page Next Page
Subscribe to Global release
  1. Home
  2. Global release

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2025

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back